国际呼吸杂志
國際呼吸雜誌
국제호흡잡지
INTERNATIONAL JOURNAL OF RESPIRATION
2008年
21期
1285-1289
,共5页
王雯%陈阳育%武宝梅%黄克武%王辰
王雯%陳暘育%武寶梅%黃剋武%王辰
왕문%진양육%무보매%황극무%왕신
哮喘%糖皮质激素(布地奈德)/长效β2受体激动剂(福莫特罗)复合制剂%肺功能%痰嗜酸粒细胞%症状
哮喘%糖皮質激素(佈地奈德)/長效β2受體激動劑(福莫特囉)複閤製劑%肺功能%痰嗜痠粒細胞%癥狀
효천%당피질격소(포지내덕)/장효β2수체격동제(복막특라)복합제제%폐공능%담기산립세포%증상
Asthma%Corticosteroids (budesonide) and long-acting β2 agonist (formoterol) powder%Lung function%Sputum eosinophil%Symptom
目的 观测联合吸入糖皮质激素(布地奈德)/长效β2受体激动剂(福莫特罗)干粉吸入剂治疗期间支气管哮喘(简称哮喘)患者诱导痰嗜酸粒细胞(EOS)计数、肺功能与哮喘临床症状的关系.方法 本院健康呼吸中心就诊的中、重度持续哮喘患者33例(哮喘组)联合吸入糖皮质激素/长效β2受体激动剂复合制剂治疗6个月,测定肺功能(FEV1、FEV1/FVC、PEF),诱导痰中EOS计数,记录哮喘控制得分(ACT)及患者哮喘生命质量评分.哮喘组在治疗开始后1个月,2个月,3个月和6个月时进行重复测定.且以10名健康者做为对照组,同期测定上述观察指标.同时记录吸入用药后的不良反应.结果 研究共纳入38例患者,共有33例完成6个月或更长的随访观察.吸入糖皮质激素/长效β2受体激动剂复合制剂治疗后1个月,FEV1值明显改善[分别为(2.53±0.46)L,(2.89±0.62)L,P<0.01];3个月后上述变化更为显著达(3.19±0.47)L,与治疗1个月后相比发生显著变化(P<0.05);哮喘组诱导痰中EOS显著升高达(0.156±0.047)×10<'6>(P<0.05),激素吸入治疗过程中可见显著性变化,3个月降至(0.072±0.015)×10<'6>,6个月后痰中EOS计数明显减少,与治疗前相比较差异有统计学意义(q=6.58,P<0.05).吸入治疗后ACT评分明显改善,从治疗前(8±5)分增加至治疗后2个月(15±6)分,治疗后3个月到(20±4)分,与治疗前相比较差异有统计学意义(F=5.72,P<0.05).治疗6个月后,患者哮喘生命质量评分明显提高(P<0.05).哮喘组中共有12例患者(36.36%)获得完全控制.结论 联合吸入糖皮质激素/长效β2受体激动剂复合制剂治疗哮喘明显改善患者肺功能,减少痰EOS计数,有较好的临床疗效,且应至少连用6个月或以上.
目的 觀測聯閤吸入糖皮質激素(佈地奈德)/長效β2受體激動劑(福莫特囉)榦粉吸入劑治療期間支氣管哮喘(簡稱哮喘)患者誘導痰嗜痠粒細胞(EOS)計數、肺功能與哮喘臨床癥狀的關繫.方法 本院健康呼吸中心就診的中、重度持續哮喘患者33例(哮喘組)聯閤吸入糖皮質激素/長效β2受體激動劑複閤製劑治療6箇月,測定肺功能(FEV1、FEV1/FVC、PEF),誘導痰中EOS計數,記錄哮喘控製得分(ACT)及患者哮喘生命質量評分.哮喘組在治療開始後1箇月,2箇月,3箇月和6箇月時進行重複測定.且以10名健康者做為對照組,同期測定上述觀察指標.同時記錄吸入用藥後的不良反應.結果 研究共納入38例患者,共有33例完成6箇月或更長的隨訪觀察.吸入糖皮質激素/長效β2受體激動劑複閤製劑治療後1箇月,FEV1值明顯改善[分彆為(2.53±0.46)L,(2.89±0.62)L,P<0.01];3箇月後上述變化更為顯著達(3.19±0.47)L,與治療1箇月後相比髮生顯著變化(P<0.05);哮喘組誘導痰中EOS顯著升高達(0.156±0.047)×10<'6>(P<0.05),激素吸入治療過程中可見顯著性變化,3箇月降至(0.072±0.015)×10<'6>,6箇月後痰中EOS計數明顯減少,與治療前相比較差異有統計學意義(q=6.58,P<0.05).吸入治療後ACT評分明顯改善,從治療前(8±5)分增加至治療後2箇月(15±6)分,治療後3箇月到(20±4)分,與治療前相比較差異有統計學意義(F=5.72,P<0.05).治療6箇月後,患者哮喘生命質量評分明顯提高(P<0.05).哮喘組中共有12例患者(36.36%)穫得完全控製.結論 聯閤吸入糖皮質激素/長效β2受體激動劑複閤製劑治療哮喘明顯改善患者肺功能,減少痰EOS計數,有較好的臨床療效,且應至少連用6箇月或以上.
목적 관측연합흡입당피질격소(포지내덕)/장효β2수체격동제(복막특라)간분흡입제치료기간지기관효천(간칭효천)환자유도담기산립세포(EOS)계수、폐공능여효천림상증상적관계.방법 본원건강호흡중심취진적중、중도지속효천환자33례(효천조)연합흡입당피질격소/장효β2수체격동제복합제제치료6개월,측정폐공능(FEV1、FEV1/FVC、PEF),유도담중EOS계수,기록효천공제득분(ACT)급환자효천생명질량평분.효천조재치료개시후1개월,2개월,3개월화6개월시진행중복측정.차이10명건강자주위대조조,동기측정상술관찰지표.동시기록흡입용약후적불량반응.결과 연구공납입38례환자,공유33례완성6개월혹경장적수방관찰.흡입당피질격소/장효β2수체격동제복합제제치료후1개월,FEV1치명현개선[분별위(2.53±0.46)L,(2.89±0.62)L,P<0.01];3개월후상술변화경위현저체(3.19±0.47)L,여치료1개월후상비발생현저변화(P<0.05);효천조유도담중EOS현저승고체(0.156±0.047)×10<'6>(P<0.05),격소흡입치료과정중가견현저성변화,3개월강지(0.072±0.015)×10<'6>,6개월후담중EOS계수명현감소,여치료전상비교차이유통계학의의(q=6.58,P<0.05).흡입치료후ACT평분명현개선,종치료전(8±5)분증가지치료후2개월(15±6)분,치료후3개월도(20±4)분,여치료전상비교차이유통계학의의(F=5.72,P<0.05).치료6개월후,환자효천생명질량평분명현제고(P<0.05).효천조중공유12례환자(36.36%)획득완전공제.결론 연합흡입당피질격소/장효β2수체격동제복합제제치료효천명현개선환자폐공능,감소담EOS계수,유교호적림상료효,차응지소련용6개월혹이상.
Objective To analyze the changes of eosinophii counts in induced sputum and lung function from patients with bronchial asthma(asthma) and their correlations to asthma clinical symptom in inhaled corticosteroids (budesonide) and long-acting β2 agonist (formoterol) powder for inhalation treatment. Methods Thirty-three outpatients with moderate to sever persistent asthma from Beijing Chaoyang Hospital Health Clinic Center were treated with combined medications of inhaled cortieosteroids plus long-acting β2 agonist for six months. Asthma control test(ACT) scores were recorded, and lung function (represented by FEV, and PEF) and eosinophil(EOS) counts in induced sputum were measured at regular intervals. Ten volunteers served as control and lung function and EOS counts in induced sputum were measured. The lung function, EOS counts in induced sputum, clinical symptoms, and adverse reaction of inhaled eortieosteroids plus long-acting β2 agonist powder for inhalation were evaluated after treatment. Results A total of 38 subjects were enrolled,of whom 33 completed six months or longer follow-up. FEV1 of 33 subjects before treatment was (2.53 ± 0.46) L, which became (2.89 ± 0. 62) L at the first month, and then maintained at a very high level (3.19±0.47) L after the third month, which showed significant difference with the first month( P<0.05). EOS counts decreased from (0.156±0.047)×106 to (0.072±0.015)×106 by the third month, EOS counts clear decreased by the six month, which was significantly different from untreatrnent( q=6.58, P<0. 05). ACT increased from (8±5) scores to (15±6) scores by the second month( q=6.83, P <0.05) ,and (20±4) scores by the third month,which showed significant difference with normal control( F=5.72, P<0.05). At the end of six months treatment,asthma quality of life scores were improved significantly( P<0.05). There were 12(36.36%) patients achieving the criteria for being well controlled. Conclusions The clinical effect of inhaled eorticosteroids plus long-acting β2 agonist powder for inhalation on asthma is satisfactory accompanied with improving lung function, better symptom control, decreased EOS counts in induced sputum, provided six months treatment had been taken.
